13,707 results match your criteria Gynecologic oncology[Journal]


An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor.

Gynecol Oncol 2019 Apr 17. Epub 2019 Apr 17.

The University of Texas MD Anderson Cancer Centre, Houston, TX, USA.

Objectives: We evaluated four different treatment regimens for advanced-stage mucinous epithelial ovarian cancer.

Methods: We conducted a multicenter randomized factorial trial (UK and US). Patients were diagnosed with primary mEOC: FIGO stage II-IV or recurrence after stage I disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.256DOI Listing

Platinum single-agent vs. platinum-based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer: A meta-analysis of randomized controlled trials.

Gynecol Oncol 2019 Apr 18. Epub 2019 Apr 18.

Department of Oncology, The Second Xiangya Hospital, Changsha, China. Electronic address:

Objectives: This study compared treatment outcomes and adverse events in patients with locally advanced cervical cancer undergoing radiotherapy (RT) with concurrent platinum-based doublet therapy vs. RT plus platinum single-agent therapy. The main outcomes were progression-free survival (PFS), overall survival (OS), and the occurrence of adverse events. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258193050
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2019.04.013DOI Listing
April 2019
2 Reads

Obturator nerve regeneration using a genito-femoral graft placed only by fibrin sealant (Tisseel®).

Gynecol Oncol 2019 Apr 17. Epub 2019 Apr 17.

Gynecologic Oncology Unit, Women Wealth Area, Department of Woman and Child Health and Public Health, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.248DOI Listing

Innervation of cervical carcinoma is mediated by cancer-derived exosomes.

Gynecol Oncol 2019 Apr 16. Epub 2019 Apr 16.

Sanford Research, Cancer Biology and Immunotherapy Group, 2301 East 60th St north, Sioux Falls, SD 57104, USA. Electronic address:

Objective: Recently, our laboratory identified sensory innervation within head and neck squamous cell carcinomas (HNSCCs) and subsequently defined a mechanism whereby HNSCCs promote their own innervation via the release of exosomes that stimulate neurite outgrowth. Interestingly, we noted that exosomes from human papillomavirus (HPV)-positive cell lines were more effective at promoting neurite outgrowth than those from HPV-negative cell lines. As nearly all cervical tumors are HPV-positive, we hypothesized that these findings would extend to cervical cancer. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258193114
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2019.04.651DOI Listing
April 2019
1 Read

Predictive factors of unexpected lymphatic drainage pathways in early-stage cervical cancer.

Gynecol Oncol 2019 Apr 16. Epub 2019 Apr 16.

Gynecologic and Breast Oncologic Surgery Department, Georges Pompidou European Hospital, Paris, France; Paris Descartes University, Sorbonne Paris Cité, Faculty of Medicine, Paris, France.

Objectives: The purpose of this study was to describe sentinel lymph nodes (SLN) topography in patients with early-stage cervical cancer and to determine factors associated with atypical lymphatic drainage pathway (LDP).

Methods: We analyzed the data of two prospective multicentric trials on SLN biopsy for cervical cancer (SENTICOL I and II) in women undergoing surgery for early-stage cervical cancer. SLN detection was realized with a combined labeling technique (Patent blue and radioactive tracer). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258193050
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2019.04.008DOI Listing
April 2019
1 Read

Delay in time to surgery and impact on survival in patients with endometrial cancer: A National Cancer Database Analysis.

Gynecol Oncol 2019 Apr 15. Epub 2019 Apr 15.

Department of Obstetrics and Gynecology, Division of Gynecologic Oncology Cleveland Clinic, Cleveland, OH, United States of America.

Objective: To determine patient and facility-specific factors associated with time to surgery (TTS) in patients with endometrial cancer (EC), and define the impact of delay in TTS >6 weeks on overall survival (OS) by tumor histology and stage.

Methods: The National Cancer Database (NCDB) was queried to identify patients with EC who underwent definitive primary surgical treatment between 2004 and 2013. Patients were stratified by EC histology into type I (endometrioid) and type II (non-endometrioid). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.244DOI Listing

Models to predict outcomes after primary debulking surgery: Independent validation of models to predict suboptimal cytoreduction and gross residual disease.

Gynecol Oncol 2019 Apr 16. Epub 2019 Apr 16.

Division of Gynecologic Surgery, Mayo Clinic, Rochester, MN, United States of America.

Objective: Treatment planning requires accurate estimation of surgical complexity (SC) and residual disease (RD) at primary debulking surgery (PDS) for advanced ovarian cancer (OC). We sought to independently validate two published computed tomography (CT) prediction models.

Methods: We included stage IIIC/IV OC patients who underwent PDS from 2003 to 2011. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.04.011DOI Listing

Long-term results of fertility-sparing treatment for early-stage cervical cancer.

Gynecol Oncol 2019 Apr 16. Epub 2019 Apr 16.

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.

Objective: To evaluate the long-term outcomes of young early stage cervical cancer patients wishing to preserve their childbearing potential.

Methods: Data of young (aged <40 years) patients with early stage cervical cancer were prospectively collected. All patients with stage IA2, IB1 and IB2 cervical cancer were included; they have cervical conization and pelvic node dissection performed via minimally invasive surgery. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258193050
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2019.04.007DOI Listing
April 2019
1 Read

Pathway to the Papanicolaou smear: The development of cervical cytology in twentieth-century America and implications in the present day.

Gynecol Oncol 2019 Apr 14. Epub 2019 Apr 14.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, United States of America.

George Papanicolaou, a Greek immigrant and cytopathologist, was responsible for what is now colloquially known as the "Pap smear"-undoubtedly one of the greatest advances in medicine and public health of the last century. However, his landmark research on the development of cervical cytology for the detection of precancerous lesions of the cervix ("New Cancer Diagnosis," 1928) made a rather inauspicious debut in an unlikely venue: John Harvey Kellogg's Third Race Betterment Conference-a meeting devoted to the furtherance of the concept and implementation of eugenics. Herein, we discuss the stark juxtaposition of Papanicolaou's landmark discovery amid the pseudoscience of the third Race Betterment Conference. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.04.004DOI Listing
April 2019
1 Read

Immunotherapy and radiation combinatorial trials in gynecologic cancer: A potential synergy?

Gynecol Oncol 2019 Apr 14. Epub 2019 Apr 14.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Immunotherapy (IO) is an important new pillar in the treatment of solid tumors, and the integration of IO agents with chemotherapy, targeted therapy, surgery and radiation has yet to be defined. As preclinical and clinical studies have described synergistic activity with the combination of radiation and immunotherapy, many clinical trials are underway to explore both the safety and efficacy of this approach both in the metastatic and definitive setting. Through immune priming, radiation may enhance local tumor control at the irradiated site, as well as induce a systemic response to control distant metastasis, known as the abscopal effect. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258193049
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2019.03.255DOI Listing
April 2019
2 Reads

Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance?

Gynecol Oncol 2019 Apr 13. Epub 2019 Apr 13.

Center for Biomarkers and Emerging Technologies, Women and Infants Hospital/Brown University, RI 02905, USA; Department of Pathology, Women and Infants Hospital/Brown University, RI 02905, USA.

Introduction: Management of a woman with a pelvic mass is complicated by difficulty in discriminating malignant from benign disease. Many serum biomarkers have been examined to determine their sensitivity for detecting malignancy. This study was designed to evaluate if the addition of biomarkers to HE4 and CA125, as used in the Risk of Malignancy Algorithm (ROMA), can improve the detection of EOC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.04.006DOI Listing

Constitutively active ESR1 mutations in gynecologic malignancies and clinical response to estrogen-receptor directed therapies.

Gynecol Oncol 2019 Apr 13. Epub 2019 Apr 13.

Duke University Medical Center, Durham, NC, United States of America.

Objective: Endocrine therapy is often considered as a treatment for hormone-responsive gynecologic malignancies. In breast cancer, activating mutations in the estrogen receptor (mutESR1) contribute to therapeutic resistance to endocrine therapy, especially aromatase inhibitors (AIs). The purpose of this study was to evaluate the frequency and clinical relevance of ESR1 genomic alterations in gynecologic malignancies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.04.010DOI Listing
April 2019
1 Read

Nine-valent HPV vaccine efficacy against related diseases and definitive therapy: comparison with historic placebo population.

Gynecol Oncol 2019 Apr 11. Epub 2019 Apr 11.

Merck & Co., Inc., Kenilworth, NJ, United States. Electronic address:

Objective: Nine-valent human papillomavirus (9vHPV) vaccine efficacy against disease and cervical surgeries related to all nine vaccine components was assessed compared with a historic placebo population. This was not assessed in the 9vHPV vaccine efficacy trial since the trial was quadrivalent HPV (qHPV) vaccine-controlled, efficacy was measured for the five HPV types covered only by 9vHPV vaccine (HPV31/33/45/52/58), but not the four types covered by both vaccines (HPV6/11/16/18).

Methods: Three international, randomized, double-blind studies were conducted using the same methodology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.253DOI Listing
April 2019
1 Read

Gynecologic oncology providers endorse practice-changing impact of communication skills training.

Gynecol Oncol 2019 Apr 9. Epub 2019 Apr 9.

Department of Medicine, Division of General Internal Medicine, Section of Palliative Care & Medical Ethics, University of Pittsburgh Medical Center, Pittsburgh, PA, United States of America.

Objective: Effective communication improves patient outcomes and is crucial to good patient care. Communication skills training (CST) has been shown to improve communication skills in non-gynecologic oncology specialties. We sought to develop and test CST for gynecologic oncology (GO) providers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.242DOI Listing

The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer.

Gynecol Oncol 2019 Apr 9. Epub 2019 Apr 9.

Clinical Trial Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, "Fondazione G.Pascale" IRCCS, Napoli, Italy. Electronic address:

Background: Cervical cancer cells often express Epidermal Growth Factor Receptor (EGFR). Cetuximab (CET), an anti-EGFR antibody, can be safely combined with carboplatin (C) and paclitaxel (P), a standard treatment for advanced/recurrent cervical cancer (ARCC) patients.

Patients And Methods: ARCC patients, ECOG PS ≤ 1, were randomized to CP for 6 cycles with or without CET (400 mg/m one week before starting CP, then 250 mg/m weekly) until disease progression or unacceptable toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.260DOI Listing
April 2019
1 Read

Metastasis-associated protein 1, modulated by miR-30c, promotes endometrial cancer progression through AKT/mTOR/4E-BP1 pathway.

Gynecol Oncol 2019 Apr 9. Epub 2019 Apr 9.

Department of Gynecology, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing 210008, People's Republic of China. Electronic address:

Objective: Though metastasis-associated protein 1 (MTA1) is widely overexpressed in human cancers and is associated with advanced clinicopathological characteristics and survival in related diseases, the association between MTA1 and endometrial cancer (EC) is little known and needs to be studied.

Methods: Western blot and immunohistochemistry were used to analyze protein expression level of cells and tissues, while real-time PCR was used for RNA detection. Bioinformatics tool analysis revealed the relationship between MTA1 and clinicopathological characteristics and survival. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.04.005DOI Listing
April 2019
1 Read
3.774 Impact Factor

Increased risk for depression persists for years among women treated for gynecological cancers - a register-based cohort study with up to 19 years of follow-up.

Gynecol Oncol 2019 Apr 8. Epub 2019 Apr 8.

Survivorship Unit, Danish Cancer Society Research Center, Copenhagen, Denmark; Department of Clinical Oncology & Palliative Care, Zealand University Hospital, Næstved, Denmark.

Objective: Little is known about long-term risk of depression in women treated for gynecological cancers. We aim to investigate risk for depression among these women compared to women without a history of cancer.

Methods: We followed 16,833 women diagnosed with gynecological cancers between 1998 and 2013 and 138,888 reference women in nationwide registers for up to 19 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.259DOI Listing

The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up.

Gynecol Oncol 2019 Apr 2. Epub 2019 Apr 2.

Roche Pharmaceutical Research & Early Development, Roche Innovation Center New York, 430 E. 29th Street New York City, New York 10016, USA. Electronic address:

Background: While prophylactic human papillomavirus (HPV) vaccination exists, women are still developing cervical intraepithelial neoplasia (CIN) grade 2 or 3 for which an immunotherapeutic, non-surgical, approach may be effective. The primary aim was to assess the efficacy of tipapkinogen sovacivec (TS) vaccine in achieving histologic resolution of CIN2/3 associated with high risk (HR) HPV types.

Methods: Women 18 years and older who had confirmed CIN2/3 were enrolled in a randomized, double blind, placebo-controlled phase II trial and assigned to drug in a 2:1 ratio (vaccine:placebo). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.250DOI Listing
April 2019
1 Read

Sentinel node mapping vs. lymphadenectomy in endometrial cancer: A systematic review and meta-analysis.

Gynecol Oncol 2019 Apr 2. Epub 2019 Apr 2.

Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy.

Sentinel node mapping is increasingly being utilized for endometrial cancer staging. However, only limited evidence supporting the adoption of sentinel node mapping instead of conventional lymphadenectomy is still available. Here, we aimed to review the current evidence comparing sentinel node mapping and lymphadenectomy in endometrial cancer staging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.254DOI Listing

Risk factors for anastomotic leakage after colorectal resection in ovarian cancer surgery: A multi-centre study.

Gynecol Oncol 2019 Apr 2. Epub 2019 Apr 2.

Department of Gynecologic Oncology Department, University Hospital La Fe, Valencia, Spain.

Objective: To determine pre-/intraoperative risk factors for anastomotic leak after modified posterior pelvic exenteration (MPE) or colorectal resection in ovarian cancer and to create a practical instrument for predicting anastomotic leak risk.

Background: In advanced ovarian cancer surgery, there is rather limited published evidence, drawn from a small sample, providing information about risk factors for anastomotic leak.

Methods: Eight hospitals participated in this retrospective study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.241DOI Listing
April 2019
2 Reads

The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer.

Gynecol Oncol 2019 Apr 1. Epub 2019 Apr 1.

Department of Gynecology, Center for Gynecologic Oncology Amsterdam (CGOA), Location The Netherlands Cancer Institute, P.O. Box 90203, 1006 BE Amsterdam, the Netherlands.

Objective: The benefit of adjuvant chemotherapy for FIGO stage I, high-grade serous ovarian cancer (HGSOC) after optimal staging is a matter of debate. We investigated the effect of adjuvant chemotherapy on recurrence-free survival (RFS) and overall survival (OS) in a population-based cohort study.

Methods: All patients diagnosed in the Netherlands between 2002 and 2014 with FIGO stage I HGSOC who underwent surgical staging were included. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258193049
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2019.03.257DOI Listing
April 2019
4 Reads

Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer.

Gynecol Oncol 2019 Mar 29. Epub 2019 Mar 29.

Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Boston, MA, United States of America; Harvard Medical School, Boston, MA, United States of America.

Polymerase-epsilon (POLE)-mutated carcinomas are a rare, but well-known subtype of endometrial cancer. While typically associated with good prognosis, recurrences are documented. Here we present a case of recurrent POLE-mutated endometrial cancer, discuss pathologic features, current methods of molecular classification, and explore therapeutic implications for the POLE-mutation phenotype. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.247DOI Listing

Determinants of health-related quality of life in elderly ovarian cancer patients: The role of frailty and dependence.

Gynecol Oncol 2019 Mar 29. Epub 2019 Mar 29.

Department of Epidemiology, University of Groningen, University Medical Center Groningen (UMCG), the Netherlands. Electronic address:

Objective: To investigate the impact of frailty and dependence on health-related quality of life (HRQOL) in elderly women diagnosed with epithelial ovarian cancer (EOC).

Methods: Data was gathered from a prospectively collected data biobank, OncoLifeS (Oncological Life Study) at the University Medical Center of Groningen. Women with a diagnosis of EOC, ≥65 years of age, with baseline assessment available from January 2016 to May 2018 were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.249DOI Listing
March 2019
2 Reads

The preventable burden of endometrial and ovarian cancers in Australia: A pooled cohort study.

Gynecol Oncol 2019 Mar 29. Epub 2019 Mar 29.

Centre for Big Data Research in Health, University of New South Wales, Sydney, Australia.

Objective: Evidence on the endometrial and ovarian cancer burden preventable through modifications to current causal behavioural and hormonal exposures is limited. Whether the burden differs by population subgroup is unknown.

Methods: We linked pooled data from six Australian cohort studies to national cancer and death registries, and quantified exposure-cancer associations using adjusted proportional hazards models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.102DOI Listing
March 2019
1 Read

The prognostic significance of aortic lymph node metastasis in endometrial cancer: Potential implications for selective aortic lymph node assessment.

Gynecol Oncol 2019 Mar 30. Epub 2019 Mar 30.

Division of Epidemiology, The Ohio State University College of Public Health, Columbus, OH, United States of America.

Objectives: To evaluate the prognostic impact of aortic vs. pelvic lymph node (LN) metastasis among women with endometrial cancer (EC).

Methods: Using data from the SEER 18 Registries we identified 3650 women with LN positive (stage IIIC) EC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.251DOI Listing
March 2019
2 Reads

Antibody-drug conjugates in gynecologic malignancies.

Gynecol Oncol 2019 Mar 28. Epub 2019 Mar 28.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA; Division of Gynecologic Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address:

Antibody drug conjugates (ADCs) are an exciting class of oncologic therapeutics. ADCs have been FDA approved in hematologic malignancies and breast cancer and are a growing area of study in numerous solid malignancies. The desire for tumor-specific therapies with decreased systemic toxicity has driven over a decade of research into the design and optimization of ADCs, which are now in a third generation of development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.245DOI Listing

Phase II trial of nintedanib in patients with bevacizumab-resistant recurrent epithelial ovarian, tubal, and peritoneal cancer.

Gynecol Oncol 2019 Mar 28. Epub 2019 Mar 28.

Division of Gynecologic Oncology, University of Virginia, United States of America.

Background: Bevacizumab provides benefit in epithelial ovarian cancer (EOC), yet resistance to bevacizumab often occurs. We determined if nintedanib, a tyrosine kinase inhibitor of VEGF, FGF, and PDGF receptors has antitumor activity in bevacizumab-resistant recurrent EOC, tubal, and peritoneal cancer.

Methods: This phase II study evaluated nintedanib 200 mg/day until disease progression or unacceptable toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.246DOI Listing
March 2019
2 Reads

Platelets promote invasion and induce epithelial to mesenchymal transition in ovarian cancer cells by TGF-β signaling pathway.

Gynecol Oncol 2019 Mar 27. Epub 2019 Mar 27.

State Key Laboratory of Molecular Oncology, Department of Clinical Laboratory, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Objective: To test whether platelets could increase invasion potential and initiate EMT in ovarian cancer cells via a TGF-β signaling pathway.

Methods: Blood samples were collected in 69 patients with ovarian cancer, 16 patients with benign ovarian tumor and 64 healthy donors. SK-OV-3 and OVCAR-3 ovarian cancer cells were treated with platelets. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.02.026DOI Listing
March 2019
5 Reads

Molecular classification defines outcomes and opportunities in young women with endometrial carcinoma.

Gynecol Oncol 2019 Mar 25. Epub 2019 Mar 25.

Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, University of British Columbia, Vancouver, British Columbia, Canada. Electronic address:

Objective: Approximately 15% of endometrial carcinomas (ECs) arise in young women who may wish to avoid surgical menopause and/or preserve fertility. Our aim was to evaluate the prognostic significance of Proactive Molecular risk classifier for Endometrial Carcinoma (ProMisE) in young (<50 yo) women with EC.

Methods: ProMisE was applied to a retrospective cohort of women with ECs <50 yo at diagnosis, and associations between the four ProMisE molecular subtypes (MMR deficient (MMRd), POLE mutated (POLE), p53 wild type (p53wt), and p53 abnormal (p53abn)) and clinicopathological parameters, including outcomes, were assessed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.098DOI Listing
March 2019
2 Reads

Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.

Gynecol Oncol 2019 Mar 22. Epub 2019 Mar 22.

University of Colorado Denver Aurora, Department of Gynecologic Oncology, CO, United States of America.

Objectives: Stage I, grade 1 endometrial cancers have low recurrence rates and often do not receive adjuvant therapy. We compared recurrent cases to matched non-recurrent controls to evaluate for molecular markers associated with higher risk of recurrence.

Methods: A case-control study including all cases of recurrent stage I, grade 1 endometrioid endometrial cancer at one institution in a ten-year period. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258193027
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2019.03.100DOI Listing
March 2019
5 Reads

Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: A JSGO-JSOG joint study.

Gynecol Oncol 2019 Mar 21. Epub 2019 Mar 21.

Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa, Japan. Electronic address:

Objective: To examine the trends of epithelial ovarian cancer histologic subtypes in Japan.

Methods: A nationwide retrospective registry study was performed between 2002 and 2015 (Japan cohort, n = 48,640). Trends were also examined in The Surveillance, Epidemiology, and End Results Program (US cohort, n = 49,936). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.243DOI Listing
March 2019
2 Reads

Shaping the standard of care in ovarian cancer management: A review of Gynecologic Oncology Group (GOG)/NRG oncology clinical trials of the past twenty years.

Gynecol Oncol 2019 Mar 22. Epub 2019 Mar 22.

Women and Infants Hospital, Alpert School of Medicine at Brown University, 101 Dudley Street, Providence, RI 02905, United States of America. Electronic address:

The Gynecologic Oncology Group (GOG), now part of the NRG Oncology network since the re-alignment of the National Clinical Trials Network in 2014, has played a fundamental role in creating the standard of care for women with ovarian cancer. GOG/NRG Oncology has had a series of achievements that have contributed to how we treat this disease; the approval of bevacizumab in frontline therapy, defining the role of intraperitoneal chemotherapy, optimal chemotherapy for early stage disease and the role of surgery in primary and recurrent disease management. Going forward, GOG/NRG Oncology is positioned to meet the ever changing knowledge that we have about the molecular background of this disease and the expanding repertoire of drugs/interventions in development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.02.020DOI Listing
March 2019
1 Read

Clinical outcomes after isolated pelvic failure in cervical cancer patients treated with definitive radiation.

Gynecol Oncol 2019 Mar 21. Epub 2019 Mar 21.

Department of Radiation Oncology, Washington University School of Medicine, United States of America. Electronic address:

Purpose: To describe clinical outcomes in patients with isolated pelvic failures after definitive radiation treatment for cervical cancer.

Methods And Materials: Cervical cancer patients with isolated pelvic failure after definitive radiation with brachytherapy boost were identified in a tertiary academic center database from 1997 to 2016. All patients received an FDG-PET scan prior to their initial treatment and at the time of their first recurrence. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.104DOI Listing
March 2019
2 Reads

Early treatment modifications improve chemotherapy adherence in ovarian cancer patients ≥70 years.

Gynecol Oncol 2019 Mar 21. Epub 2019 Mar 21.

Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein, Kiel, Germany; Onkologisches Therapiezentrum, Krankenhaus Jerusalem, Hamburg, Germany.

Objective: Elderly ovarian cancer patients are underrepresented in clinical trials and disadvantaged with regard to therapeutic standards compared to other age groups. We explored the specific performance of a subset of patients aged ≥70 years in a large meta-data set of 3 phase III trials.

Methods: 3333 patients with advanced ovarian cancer recruited into 3 clinical phase III trials of the AGO & GINECO study groups were retrospectively analysed for age-specific prognostic and toxicity parameters. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.02.015DOI Listing
March 2019
2 Reads

Chloride channel-3 is required for efficient tumour cell migration and invasion in human cervical squamous cell carcinoma.

Gynecol Oncol 2019 Mar 21. Epub 2019 Mar 21.

Department of Obstetrics and Gynecology, The First People's Hospital of Foshan, Foshan, China. Electronic address:

Objective: Chloride channel-3 (ClC-3) plays significant roles in various physiological and physiopathological activities, including cell migration and invasion ability. The purpose of this study was to evaluate whether ClC-3 influences the migration and invasion of cervical squamous cell carcinoma cells and its possible mechanisms.

Methods: Paraffin-embedded cervical tissues, including normal cervical tissues, cervical squamous cell carcinoma (SCC) and homologous paracancerous tissues, were collected. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.006DOI Listing
March 2019
1 Read

SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma.

Gynecol Oncol 2019 Mar 20. Epub 2019 Mar 20.

Department of Pathology, Oslo University Hospital, Norwegian Radium Hospital, N-0310 Oslo, Norway; University of Oslo, Faculty of Medicine, Institute of Clinical Medicine, N-0316 Oslo, Norway. Electronic address:

Objective: The aim of this study was to analyze the expression, biological role and clinical relevance of cancer stem cell markers in high-grade serous carcinoma (HGSC).

Methods: mRNA expression by qRT-PCR of NANOG, OCT4, SOX2, SOX4, SOX9, LIN28A and LIN28B was analyzed in 134 HGSC specimens (84 effusions, 50 surgical specimens). Nanog, OCT3/4, SOX2 and SOX9 protein expression by immunohistochemistry was analyzed in 52 HGSC effusions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.099DOI Listing
March 2019
1 Read

Patient characteristics and opioid use prior to discharge after open gynecologic surgery in an enhanced recovery after surgery (ERAS) program.

Gynecol Oncol 2019 Mar 19. Epub 2019 Mar 19.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address:

Objective: To identify clinical and demographic characteristics associated with the absence of opioid usage on the day before discharge among patients undergoing open gynecologic surgery within an enhanced recovery after surgery (ERAS) program.

Methods: This was a single institution retrospective cohort study including all patients who underwent elective open gynecologic surgery as part of an ERAS program between November 1, 2014 and September 30, 2018 and who were discharged between post-operative day 2 and 7. Patients were excluded if they reported pre-existing chronic opioid use or underwent total pelvic exenteration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.101DOI Listing
March 2019
2 Reads

Green versus blue: Randomized controlled trial comparing indocyanine green with methylene blue for sentinel lymph node detection in endometrial cancer.

Gynecol Oncol 2019 Mar 19. Epub 2019 Mar 19.

Gynecologic Oncology Service, Department of Obstetrics and Gynecology, Centre Hospitalier de l'Université de Montréal, 1000 Rue Saint-Denis, Montréal, QC H2X 0C1, Canada. Electronic address:

Objective: To ascertain the increase in detection rate of sentinel lymph node (SLN) associated with the use of indocyanine green (ICG) in comparison with methylene blue dye in women with endometrial cancer.

Methods: For this randomized controlled trial, all patients underwent SLN mapping after injection of blue dye on one side of the cervix and ICG on the other side. Randomization was for the side (right vs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.103DOI Listing

Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women.

Gynecol Oncol 2019 Mar 19. Epub 2019 Mar 19.

Cancer Prevention and Control, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA; Community and Population Health Research Institute, Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Objective: Genome-wide association studies (GWASs) for epithelial ovarian cancer (EOC) have focused largely on populations of European ancestry. We aimed to identify common germline variants associated with EOC risk in Asian women.

Methods: Genotyping was performed as part of the OncoArray project. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.02.023DOI Listing
March 2019
4 Reads
3.774 Impact Factor

The change in landscape after a new landmark is constructed: Radical hysterectomy for early cervical cancer and Minimally Invasive Surgery.

Authors:
Mario M Leitao

Gynecol Oncol 2019 Apr;153(1):1-2

Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.009DOI Listing
April 2019
1 Read

Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.

Gynecol Oncol 2019 Mar 18. Epub 2019 Mar 18.

Department of Pathology, Erasmus MC, University Medical Centre Rotterdam, the Netherlands. Electronic address:

Objectives: Carriers of BRCA1 and BRCA2 mutations are at increased risk of high grade serous carcinoma and are therefore offered risk-reducing salpingo-oophorectomy (RRSO) by 40-45 years. Most of these carcinomas are believed to arise in the fallopian tube from serous tubal intraepithelial carcinoma (STIC). We conducted a retrospective study on the prevalence of high grade serous carcinoma and STIC in BRCA1/2 carriers presenting for RRSO, and their follow-up. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258193015
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2019.03.003DOI Listing
March 2019
3 Reads

Identifying disparities in germline and somatic testing for ovarian cancer.

Gynecol Oncol 2019 Mar 16. Epub 2019 Mar 16.

Division of Gynecologic Oncology, Department of Obstetrics & Gynecology, University of Miami School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL, United States of America.

Objective: Germline mutations occur in approximately 25% of patients with epithelial ovarian cancers while somatic BRCA mutations are estimated at 5-7%. The objectives of this study were to determine the rate of germline and somatic testing in women with ovarian cancer and to identify disparities in testing at a comprehensive cancer center (CCC) and a safety net hospital (SNH).

Methods: Patients treated for ovarian cancer from 2011 to 2016 were included. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258193015
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2019.03.007DOI Listing
March 2019
12 Reads

A pilot study of lower extremity lymphedema, lower extremity function, and quality of life in women after minimally invasive endometrial cancer staging surgery.

Gynecol Oncol 2019 Mar 15. Epub 2019 Mar 15.

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Duke University, Durham, NC, United States of America; Duke Cancer Institute, Durham, NC, United States of America.

Objective: The primary aim of this study was to pilot the use of an objective measurement technique to prospectively evaluate the incidence of lower extremity lymphedema (LEL) after minimally invasive staging surgery for endometrial cancer. Secondary objectives included observation of changes in lower extremity function and quality of life in this patient population.

Methods: A prospective evaluation of LEL was performed in 97 women who underwent minimally invasive staging surgery for endometrial cancer using comparative circumferential volume measurements. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.02.021DOI Listing
March 2019
2 Reads

Uptake of sentinel lymph node procedures in women with vulvar cancer over time in a population based study.

Gynecol Oncol 2019 Mar 12. Epub 2019 Mar 12.

University of Toronto, Department of Obstetrics and Gynecology, Toronto, Ontario, Canada; Division of Gynecologic Oncology, Odette Cancer Centre, Toronto, Ontario, Canada; Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada. Electronic address:

Objectives: To evaluate trends in uptake of sentinel lymph node (SLN) procedures over time and associated factors in women with vulvar cancer.

Methods: A retrospective population-based cohort study identified women with invasive squamous cell carcinoma (SCC) of the vulva using health administrative data for the province of Ontario, Canada, between 2008 and 2016. Patients who underwent SLN procedures were compared to those who had groin node dissection (GND). Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258193015
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2019.03.010DOI Listing
March 2019
5 Reads

Increased risk of brain metastases in ovarian cancer patients with BRCA mutations.

Gynecol Oncol 2019 Mar 12. Epub 2019 Mar 12.

Harvard Medical School, Hematology/Oncology, Massachusetts General Hospital, 55 Fruit Street, Yawkey 9E, Boston, MA 02114, USA. Electronic address:

Purpose: To estimate the risk for brain metastases in patients with ovarian cancer using real-world data, and assess whether BRCA mutations increase that risk.

Methods: This retrospective study included 4515 patients diagnosed with ovarian cancer between January 1, 2011, and January 31, 2018, from the Flatiron Health database, a longitudinal, demographically, and geographically diverse database derived from electronic health records in the United States.

Results: Forty-six (1%) patients were diagnosed with brain metastases after being diagnosed with ovarian cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2019.03.004DOI Listing

Measuring cause-and-effect relationships without randomized clinical trials: Quasi-experimental methods for gynecologic oncology research.

Gynecol Oncol 2019 03;152(3):533-539

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons, New York, NY, United States of America.

Clinical research in gynecologic oncology has seen a proliferation of studies that investigate the effectiveness of treatments using existing data sources such as cancer registries, electronic health records, and insurance claims. These observational studies are often feasible when randomized trial may not be, and may be more generalizable than randomized trials, because of greater diversity in the study populations. While statistical methods such as multivariable regression, matching, stratification, and weighting can adjust for the confounding in observational studies, statistical adjustment cannot control for confounders that are unmeasured in the data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.11.006DOI Listing

Cervical cancer radiation therapy compliance rates based on location of radiation therapy.

Gynecol Oncol 2019 03;152(3):528-532

Ohio Heath Gynecologic Cancer Surgeons, Riverside Methodist Hospital, Medical Education, United States of America.

Objective: Completion of radiation therapy (RT) within 60 days has been proposed as a national quality measure for patients with carcinoma of the cervix as protracted RT has been associated with worse oncologic outcomes. The objective of this study was to compare compliance rates based on location of RT administration.

Methods: This was a retrospective chart review of patients diagnosed with cervical cancer between January of 2000 to December of 2016 who were planned to undergo primary treatment with sensitizing chemotherapy and RT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.09.011DOI Listing

Evolving trends in the management of high-intermediate risk endometrial cancer in the United States.

Gynecol Oncol 2019 03;152(3):522-527

Department of Radiation Oncology, University of Colorado Cancer Center, Aurora, CO, United States of America. Electronic address:

Objective: Gynecologic oncology group protocol 249 (GOG 249) is the contemporary US study that aimed to define the standard of care adjuvant therapy for patients with high-intermediate risk (HIR) endometrial cancer; patients were randomized to pelvic radiation therapy (RT) or vaginal brachytherapy (VBT) with chemotherapy (VBT-C). The preliminary results of GOG 249 were recently presented, yet the management of patients represented in this trial remains controversial. We set out to review US patterns of care for patients meeting eligibility criteria for GOG 249. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258183147
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2018.12.010DOI Listing
March 2019
6 Reads

Women's preferences for cancer risk management strategies in Lynch syndrome.

Gynecol Oncol 2019 03;152(3):514-521

The University of Texas MD Anderson Cancer Center, Department of Behavioral Sciences, Houston, TX, United States of America.

Objective: We assessed preferences for cancer risk management strategies for Lynch syndrome (LS) in LS-affected women.

Methods: Women with LS aged ≥25 years evaluated 9 cancer risk management strategies using a visual analog scale (VAS) and modified standard gamble (SG). For the VAS, women ranked each strategy ranging from 0 (least preferred) to 100 (most preferred). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.11.027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422049PMC
March 2019
6 Reads

Utilizing the Patient Reported Outcomes Measurement Information System (PROMIS®) to increase referral to ancillary support services for severely symptomatic patients with gynecologic cancer.

Gynecol Oncol 2019 03;152(3):509-513

Montefiore Medical Center, Department of Obstetrics & Gynecology and Women's Health, Bronx, NY, United States of America; Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, NY, United States of America.

Objective: The Patient-Reported Outcomes Measurement Information System (PROMIS®) Network has developed a comprehensive repository of electronic patient reported outcomes measures (ePROs) of major symptom domains that have been validated in cancer patients. Their use for patients with gynecologic cancer has been understudied. Our objective was to establish feasibility and acceptability of PROMIS ePRO integration in a gynecologic oncology outpatient clinic and assess if it can help identify severely symptomatic patients and increase referral to supportive services. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2018.10.042DOI Listing
March 2019
2 Reads